ONCY — ONCOLYTICS BIOTECH INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1129928 ·
Last close
$0.38
Market Cap
$50.15M
52W High
$1.30
52W Low
$0.33
ADV30
1,298,206
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -9,742,000 | -9,705,000 | 5,832,000 | 2,430,000 | 13,335,000 |
| Jun 2026 | 0 | — | -9,379,000 | -9,442,000 | 7,671,000 | 4,115,000 | 13,838,000 |
| Mar 2026 | 0 | — | -9,281,000 | -9,243,000 | 8,161,000 | 5,493,000 | 13,291,000 |
| Dec 2025 | 0 | — | -9,651,891 | -9,177,897 | 7,582,000 | 5,202,000 | 11,381,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,704,000
Investing CF
$-11,000
Financing CF
$20,228,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.32
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-448,180,000
Inventory
—
Receivables
$1,214,000
ST Investments
—
EBIT TTM
$-38,256,205
Pretax Income TTM
$-38,090,657
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,725,000 | -28,759,000 | 7,582,000 | 11,381,000 | -3,799,000 | -20,112,000 |
| Dec 2024 | 0 | -25,542,000 | -22,794,000 | 13,421,000 | 10,123,000 | 3,298,000 | -19,883,000 |
| Dec 2023 | 0 | -25,471,883 | -20,919,644 | 29,262,777 | 8,485,602 | 20,777,175 | -21,444,294 |
| Dec 2022 | 0 | -19,837,902 | -18,298,703 | 27,508,105 | 7,981,138 | 19,526,967 | -17,208,223 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$7,671,000
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PDSB | PDS Biotechnology Corp | $50.03M | $0.89 | — |
| HOWL | Werewolf Therapeutics, Inc. | $51.03M | $1.05 | — |
| APLM | Apollomics Inc. | $49.09M | $16.84 | — |
| MIST | Milestone Pharmaceuticals Inc. | $51.44M | $0.41 | — |
| NMAD | NOMAD POWER SOLUTIONS, INC. | $48.30M | $3.00 | — |
News headlines (Yahoo Finance, 1h cache)
ONCY: Supply Agreement with Coherus to Evaluate Pelareorep in SCAC with Checkpoint Inhibitor
2026-11-16 13:05 · Yahoo
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
2026-11-13 17:10 · Yahoo
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
2026-11-09 14:30 · Yahoo
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
2026-11-04 14:30 · Yahoo
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
2026-10-27 13:30 · Yahoo
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
2026-10-20 13:35 · Yahoo
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
2026-10-14 13:30 · Yahoo
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
2026-10-14 08:07 · Yahoo
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
2026-10-12 20:05 · Yahoo
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC
2026-08-27 10:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.